I graduated from Shanghai Medical University and later came to the U.S. and obtained a PhD in molecular biology at the Medical College of Ohio. I did research in cancer biology at UPENN and then Yale as a postdoctoral associate. I completed an internal medicine residency at the Yale-affiliated Hospital of Saint Raphael program and trained in Einstein/Montefiore Medical Center during hematology and oncology fellowship. After that, I joined Cornell University Medical College and New York Presbyterian Hospital as Assistant Professor specializing in GI cancers, and clinical investigator involved in both clinical and translational research. I was the Cornell site PI for several early and late phase clinical trials including the phase 1 CXCR4 inhibitor AMD3100/Plerixafor immunotherapy trial, and wrote the protocol for an investigator-initiated trial (IIT) of high-dose IV vitamin C in solid tumors, which subsequently won a SU2C award for Cornell. In 2017, I left Cornell and joined Merck as a Director of oncology research and led several global Phase I-III immuno-oncology trials including Keynote 177 and 164 in MSI-H colorectal cancer, and Keynote 651 in non-MSI-H CRC. Most recently, I led the designing and protocol writing of a Phase III study of combinational immunotherapy vs standard of care chemotherapy in third line non-MSI-H CRC.
Although developing novel immunotherapy at Merck for cancer patients with high unmet need is very gratifying, I missed direct patient care. Thus, I returned to academic and joined Roswell Park on 8/1/2019 to focus on head and neck cancer patient care and clinical/translational research. I will also provide care for patients with lung cancer, as well as, participating in the running of phase I program to investigate safety and early efficacy of new drugs and combinations.
1. Le D; Kim, TW; Van Cutsem E; Geva R; Jaeger D; Hara H; Burge M; O’Neill B; Kavan P; Yoshino T; Guimbaud R; Taniguchi H; Elez E; Al-Batran SE; Boland PM; Crocenzi T; Altreya CE; Liang LW; Marinello P; Dai T; Diaz L; Andre T. A phase 2, open-label, study of single agent pembrolizumab in treatment refractory mismatch repair deficient metastatic colorectal cancer: the KEYNOTE-164 study. Submitted to J Clin Oncol. Aug 2019.
2. Klute KA, Brouwer J, Jhawer M, Sachs H, Gangadin A, Ocean A, Popa E, Dai T, Wu G, Christos P, Shah MA. Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. Eur J Cancer. 2016 Aug;63:189-200.
3. Ng J and Dai T, Radiation Therapy and the Abscopal Effect: A Concept Comes of Age (Editorial). Annals of Translational Medicine, 2016;4(6):118.
4. Dai T, Shah MA. Chemoradiation in Esophageal Cancer. Best Practice & Research: Clinical Gastroenterology. 2015 Feb;29(1):193-209.
5. Dai T, Popa E, Shah MA. The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies. Curr Treat Options Oncol. 2014 Sep;15(3):351-64.